Literature DB >> 33290869

Cdc20 induces the radioresistance of bladder cancer cells by targeting FoxO1 degradation.

Lixia Wang1, Chuanlai Yang2, Man Chu3, Zhi-Wei Wang4, Boxin Xue5.   

Abstract

Ionizing radiation is a conventional therapy for cancer patients, but patients often experience distant metastasis and recurrence, which lead to a poor prognosis after the implementation of this treatment. Moreover, the underlying mechanisms by which radioresistance contributes to metastatic potential is still elusive. Here, we explored the molecular mechanisms that contribute to radioresistance in bladder cancer. To achieve this, we established two irradiation-resistant (IR) cell lines, T24R and 5637R, which were derived from parental bladder cancer cell lines. Cell viability was detected by CCK-8 assay, while migration and invasion abilities were examined by wound healing and Transwell chamber assays, respectively. Furthermore, the role of Cdc20 in the regulation of epithelial to mesenchymal transition (EMT) in IR cells was explored by Western blotting, immunoprecipitation and immunofluorescence staining. The IR cells exhibited EMT properties, and our data showed that Cdc20 expression was significantly elevated in IR cells. Remarkably, Cdc20 silencing reversed the EMT phenotype in IR cells. Mechanistically, Cdc20 governed IR-mediated EMT in part by governing forkhead box O1 (FoxO1) degradation. Taken together, our findings showed that the inactivation of Cdc20 or the activation of FoxO1 might be a potential strategy to overcome radioresistance in bladder cancer.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bladder cancer; Cdc20; EMT; FoxO1; Radioresistance

Year:  2020        PMID: 33290869     DOI: 10.1016/j.canlet.2020.11.052

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  7 in total

1.  CDC20 is a novel biomarker for improved clinical predictions in epithelial ovarian cancer.

Authors:  Xiaoxue Xi; Tianyue Cao; Yonghong Qian; Huiling Wang; Songwen Ju; Youguo Chen; Ting Chen; Jian Yang; Biaoquan Liang; Shunyu Hou
Journal:  Am J Cancer Res       Date:  2022-07-15       Impact factor: 5.942

Review 2.  The FOXO family of transcription factors: key molecular players in gastric cancer.

Authors:  Ying Liu; Xiang Ao; Yi Jia; Xiaoge Li; Yu Wang; Jianxun Wang
Journal:  J Mol Med (Berl)       Date:  2022-06-10       Impact factor: 5.606

3.  The bioinformatics and experimental analysis of the novel roles of virus infection-associated gene CDC20 for prognosis and immune infiltration in hepatocellular carcinoma.

Authors:  Juanni Li; Xiaofang Zhang; Lei Yao; Kuan Hu
Journal:  Aging (Albany NY)       Date:  2022-05-27       Impact factor: 5.955

4.  Screening diagnostic markers for acute myeloid leukemia based on bioinformatics analysis.

Authors:  Wenting Chen; Dan Liu; Guyun Wang; Yanping Pan; Shuwen Wang; Ruimei Tang
Journal:  Transl Cancer Res       Date:  2022-06       Impact factor: 0.496

5.  Identification of CDC20 as an immune infiltration-correlated prognostic biomarker in hepatocellular carcinoma.

Authors:  Chen Xiong; Zhihuai Wang; Guifu Wang; Chi Zhang; Shengjie Jin; Guoqing Jiang; Dousheng Bai
Journal:  Invest New Drugs       Date:  2021-05-03       Impact factor: 3.850

6.  Replication Stress: A Review of Novel Targets to Enhance Radiosensitivity-From Bench to Clinic.

Authors:  Yuewen Zhang; Lei Wu; Zhao Wang; Jinpeng Wang; Shrabasti Roychoudhury; Bartlomiej Tomasik; Gang Wu; Geng Wang; Xinrui Rao; Rui Zhou
Journal:  Front Oncol       Date:  2022-07-08       Impact factor: 5.738

7.  Polygenic risk modeling of tumor stage and survival in bladder cancer.

Authors:  Mauro Nascimben; Lia Rimondini; Davide Corà; Manolo Venturin
Journal:  BioData Min       Date:  2022-09-30       Impact factor: 4.079

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.